key: cord-0935785-ubgn5g31
authors: Nicolau, Dan V; Bafadhel, Mona
title: Inhaled corticosteroids in virus pandemics: a treatment for COVID-19?
date: 2020-07-30
journal: Lancet Respir Med
DOI: 10.1016/s2213-2600(20)30314-3
sha: e9975bc5dfd7dafb5bde054604ea68cb47e2dfe1
doc_id: 935785
cord_uid: ubgn5g31

nan

By contrast with clinical trial results, epidemiological data has suggested that corticosteroids might be associated with worse clinical outcomes. An epidemiological study from the OpenSAFELY group suggests that the use of inhaled corticosteroids (ICS) in patients with asthma and chronic obstructive pulmonary disease (COPD) is associated with worse clinical COVID-19 outcomes. 6 These findings might suggest that ICS use is not of benefit in patients with COVID-19, but this conclusion cannot be drawn from these data. First, as the OpenSAFELY authors observe, patients who were given ICS had more comorbidities than did those not given inhaled corticosteroids, a recognised risk factor for adverse COVID-19 outcomes; and second, most of the patients with asthma and COPD in this cohort did not develop or die from COVID-19. Therefore, we argue that the null hypothesis of no benefit from ICS in COVID-19 has yet to be fully explored.

ICS could be a therapeutic intervention for COVID-19 for several reasons. First, ICS use in patients at risk of acute respiratory distress syndrome (ARDS) has been shown to improve physiology and reduce levels of inflammatory markers. 7 A 50% reduction in ARDS was seen in at-risk patients who were using ICS before admission to hospital, even after controlling for age, sex, and chronic respiratory diseases. 8 Moreover, ICS use also appears to improve pulmonary physiology. 9 Second, in-vitro data suggest a role for ICS in the inhibition of coronavirus replication (including SARS-CoV-2) in infected epithelial cells. 10 Investigation of gene expression of ACE2 and TMPRSS2 in the sputum of patients with asthma has shown reduced expression of these receptors in the presence of ICS 11 and attenuation of ACE2 receptors in human and murine in-vitro and in-vivo models. 12 These findings are highly relevant because SARS-CoV-2 pathology involves TMPRSS2 for spike-protein priming and direct action on the ACE2 receptor, which is highly expressed on epithelial cells in oral mucosa and type 2 alveolar cells. Since evidence exists of accelerated hyperinflammation at the onset of SARS-CoV-2 infection, this hyperinflammation is potentially modifiable by anti-inflammatory treatment. These data suggest a plausible mechanism for efficacy of ICS against COVID-19. We would propose that ICS could have a dual role: first, reducing the inflammatory ARDS-like response affecting a minority of patients with COVID-19; and second, directly inhibiting viral replication (appendix p 1).

Unlike other viral respiratory endemics (eg, influenza), we now know that comorbid chronic respiratory conditions are probably not a major risk factor in patients with COVID-19. The absence of an increased incidence of asthma and COPD has been noted in several countries that have described the clinical characteristics of patients with COVID-19. 13 Globally, China has the highest burden of COPD, yet in a pooled analysis of 45 000 patients with COVID-19, fewer than 2% had a respiratory illness. 13 In early reports from Wuhan Province, China, only 1·1% of people with COVID-19 were noted to have COPD, while asthma was not even reported in this report. 14 These observations for ICS-while certainly not forming a complete pictureshould not be ignored, especially since one would expect patients with pre-existing, serious lung conditions to be over-represented, not under-represented, among those with COVID-19 disease.

Whether use of ICS protects against COVID-19 is still unknown, but to dismiss this hypothesis as nonsense is premature. ICS as a therapeutic intervention still need to studied and clinical trials assessing their efficacy in 

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance

Dexamethasone in hospitalized patients with COVID-19-preliminary report

Inhaled corticosteroid use and risk COVID-19 related death among 966,461 patients with COPD or asthma: an OpenSAFELY analysis

Inhalation therapies in acute respiratory distress syndrome

Preadmission use of inhaled corticosteroids is associated with a reduced risk of direct acute lung injury/acute respiratory distress syndrome

Randomized clinical trial of a combination of an inhaled corticosteroid and beta agonist in patients at risk of developing the acute respiratory distress syndrome

Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells

COVID-19-related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids

Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

Clinical characteristics of coronavirus disease 2019 in China